Health and Healthcare
Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)
Published:
Medivation, Inc. (NASDAQ: MDVN) is today’s darling in biotech and emerging pharmaceuticals. It and partner Astellas in Japan showed very positive data on its prostate cancer drug candidate.
Its shares are up more than 100% after clinical data on its prostate cancer drug candidate showed to be so effective. Medivation has even halted the clinical trial so that it can give the medicine to all participants.
The MDV3100 tial was in the final development stage for potential U.S. FDA marketing approval. The interim data indicated that patients lived an average of 4.8 months longer than those on a placebo.
That is going to only be added pressure for Dendreon Corporation (NASDAQ: DNDN). Its stock was down on its own earnings and disappointing Provenge sales figures. With the potential added competition on top of bad results, Dendreon’s stock is off by 35% to $6.77 and shares put in a new 52-week low of $6.56 this morning.
Medivation is up 113% at $35.10 and we are already more than ten-times normal trading volume.
JON C. OGG
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
